Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw

Launched by UNIVERSITY HOSPITAL, TOULOUSE · May 16, 2024

Keywords

ClinConnect Summary

Resulting in bone loss, infection, pain or discomfort, the presence of MRONJ decreases the quality of life of patients. There isn't any consensus about the treatment modalities for MRONJ, nor about its main goals. Traditionally, therapeutics only aimed to control and prevent the progression of the disease, but recent studies suggest that a whole resolution can currently be expected, especially from surgical therapies. These, when indicated, are not only intended for the removal of the pathological tissue, but above all for an hermetic mucosal healing, preventing secondary infection of the u...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • MRONJ requiring surgical treatment according to AAOMS criteria (stage 2 or 3; failure of first-line treatments; sequestration of a necrotic bone block), the resection of which needs general anesthesia;
• • Affiliates or beneficiaries of a social security scheme.
• • Having given free and informed written consent.
• Exclusion Criteria:
• • Presence of a maxillo-mandibular neoplastic lesion;
• • Presence of several MRONJ lesions;
• • History of cervico-facial radiotherapy;
• • Contraindication to general anesthesia;
• • Reduced life expectancy (estimated at less than 6 months).

Trial Officials